I7276
Anti-Insulin-Like Growth Factor-II antibody produced in goat
affinity isolated antibody, lyophilized powder
Sinônimo(s):
Anti-IGF-II
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Produtos recomendados
fonte biológica
goat
Nível de qualidade
conjugado
unconjugated
forma do anticorpo
affinity isolated antibody
tipo de produto de anticorpo
primary antibodies
clone
polyclonal
Formulário
lyophilized powder
reatividade de espécies
human
técnica(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 5-15 μg/mL using human Placenta
neutralization: 0.2-0.8 μg/mL
western blot: suitable
nº de adesão UniProt
temperatura de armazenamento
−20°C
modificação pós-traducional do alvo
unmodified
Informações sobre genes
human ... IGF2(3481)
Descrição geral
Insulin-like growth factors -I and -II are important regulators of signalling that mediates growth and metabolism in cells. Insulin-like growth factor -II (IGF-II) is widely expressed during embryonic stages and regulates the placental development. IGF-II acts via specific receptor, IGF-IIR, the binding does not result in signal transduction, but is a mechanism to restrict the bioavailability of IGF-II. IGF-II also binds to IGF-IR which results in the activation of MAPK, Raf/Ras and PI3K cascades. The effects of IGF-II signalling are important in growth of blood vessels (angiogenesis) gene transcription, proliferation and transformation. Irregular IGF-II signaling has been implicated in many cancers including lung cancer, colo-rectal cancer, cervical cancer, testicular cancer, rhabdosarcoma, melanoma and hepatoblastoma
Anti-IGF-II recognizes human insulin-like growth factor II. It does not react with human IGF-I.
Anti-IGF-II recognizes human insulin-like growth factor II. It does not react with human IGF-I.
Especificidade
The antibody will neutralize the biological activity of recombinant human IGF-II. It does not neutralize the biological activity of recombinant human IGF-I.
Imunogênio
recombinant human IGF-II
Aplicação
Anti- IGF-II antibody may be used for neutralization reactions, the ND50 of the antibody is 0.2-0.8 μg/ml. This antibody was used to neutralize IGF-II in glioblastoma cell lines. For immunohistochemistry a working antibody concentration of 5-15 μg/ml may be used for formalin-fixed, paraffin-embedded human placenta sections. The antibody is suitable for immunoblotting.
forma física
Lyophilized from a 0.2 μm filtered solution of phosphate buffered saline, pH 7.4, with 5% trehalose
Exoneração de responsabilidade
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Não está encontrando o produto certo?
Experimente o nosso Ferramenta de seleção de produtos.
produto relacionado
Nº do produto
Descrição
Preços
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 1
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Equipamento de proteção individual
Eyeshields, Gloves, type N95 (US)
Escolha uma das versões mais recentes:
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Antonino Belfiore et al.
Endocrine reviews, 30(6), 586-623 (2009-09-16)
In mammals, the insulin receptor (IR) gene has acquired an additional exon, exon 11. This exon may be skipped in a developmental and tissue-specific manner. The IR, therefore, occurs in two isoforms (exon 11 minus IR-A and exon 11 plus
Ramaswamy Suvasini et al.
The Journal of biological chemistry, 286(29), 25882-25890 (2011-05-27)
Glioblastoma is the most common and malignant form of primary astrocytoma. Upon investigation of the insulin-like growth factor (IGF) pathway, we found the IGF2BP3/IMP3 transcript and protein to be up-regulated in GBMs but not in lower grade astrocytomas (p <
Robert G Maki
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(33), 4985-4995 (2010-10-27)
Insulin-like growth factors were discovered more than 50 years ago as mediators of growth hormone that effect growth and differentiation of bone and skeletal muscle. Interest of the role of insulin-like growth factors in cancer reached a peak in the
Wendy Chao et al.
Cytokine & growth factor reviews, 19(2), 111-120 (2008-03-01)
Insulin-like growth factor II (IGF2) is perhaps the most intricately regulated of all growth factors characterized to date. Its gene is imprinted--only one allele is active, depending on parental origin--and this pattern of expression is maintained epigenetically in almost all
O Manousos et al.
International journal of cancer, 83(1), 15-17 (1999-08-17)
Recent data suggest that the IGF system plays an important role in the pathogenesis of several forms of human cancer, and there is evidence that IGFs acting in an autocrine and paracrine manner may also affect colorectal cancer risk. We
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica